Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.50 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.45 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.91 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.91 |
| ▸ | CASP1 | P29466 | 1/20 | 0.91 |
| ▸ | CASP7 | P55210 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL39679 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL367451 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3134351 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL39680 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL9099015 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6753846 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30108424 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5964581 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21523286 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7154212 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4677353-A1 | SYSTEM FOR LABEL-FREE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2024191912-A1 | SYSTEM FOR LABEL-FREE ELECTROCHEMICAL SENSING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024177860-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240019426-A1 | Lateral Flow Devices for High Sensitivity Detection of Coronavirus Infection, and Methods of Making and Using the Same | SORRENTO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| CN-117280211-A | Lateral flow device for high sensitivity detection of coronavirus infection and methods of making and using the same | 索伦托药业有限公司 | 2023-12-22 | — | — | CN | claimed |
| EP-4241085-A1 | LATERAL FLOW DEVICES FOR HIGH SENSITIVITY DETECTION OF CORONAVIRUS INFECTION, AND METHODS OF MAKING AND USING THE SAME | Sorrento Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| US-20220276237-A1 | COMPOSITIONS AND METHODS FOR ANTIGEN DETECTION INCORPORATING INORGANIC NANOSTRUCTURES TO AMPLIFY DETECTION SIGNALS | WASHINGTON STATE UNIVERSITY (US) | 2022-09-01 | — | — | US | claimed |
| WO-2022098782-A1 | LATERAL FLOW DEVICES FOR HIGH SENSITIVITY DETECTION OF CORONAVIRUS INFECTION, AND METHODS OF MAKING AND USING THE SAME | SORRENTO THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| EP-4702354-A1 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | Wallac OY (FI) | 2026-03-04 | — | — | EP | disclosed |
| EP-4677353-A1 | SYSTEM FOR LABEL-FREE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12523590-B1 | Sensing plastics with electrode sensor to monitor fluid environments | Florida Polytechnic University (US) | 2026-01-13 | — | — | US | disclosed |
| US-12508299-B2 | Compositions and methods for treating obesity and hyperphagia | METROHEALTH VENTURES LLC (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025217532-A1 | DEVICES AND METHODS FOR DETECTING DISEASES | CONTROLPOINT INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304675-A1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASE | METROHEALTH VENTURES LLC (US) | 2025-10-02 | — | — | US | disclosed |
| US-8134146-B2 | Heterocyclic radical or diradical, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, the use thereof, organic semiconductive material and electronic or optoelectronic component | NOVALED AG (DE) | 2012-03-13 | — | — | US | disclosed |
| EP-1837926-B1 | Heterocyclic radicals or diradicals and their dimers, oligomers, polymers, di-spiro and polycyclic derivatives as well as their use in organic semiconductor materials and electronic devices. | NOVALED AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070252140-A1 | Heterocyclic Radical or Diradical, the Dimers, Oligomers, Polymers, Dispiro Compounds and Polycycles Thereof, the Use Thereof, Organic Semiconductive Material and Electronic or Optoelectronic Component | NOVALED AG (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1837926-A1 | Heterocyclic radicals or diradicals and their dimers, oligomers, polymers, di-spiro and polycyclic derivatives as well as their use in organic semiconductor materials and electronic devices. | Novaled AG (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508299-B2 | Compositions and methods for treating obesity and hyperphagia | GIPR, GPR119, GLP1R | GAA 1562/4885PIK3CA 711/4885ADRA2B 1253/4885 |
| US-20070252140-A1 | Heterocyclic Radical or Diradical, the Dimers, Oligomers, Polymers, Dispiro Compounds and Polycycles Thereof, the Use Thereof, Organic Semiconductive Material and Electronic or Optoelectronic Component | PPOX, SCO2, CCNO | GAA 4873/4885PIK3CA 2048/4885ADRA2B 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.